ArticleFrontiers in bioengineering and biotechnology2026
Development of a gene-activated matrix for enhanced AAV gene delivery
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant AAV vectors are among the most extensively studied vectors for viral gene delivery due to their unique safety profile and their ability to mediate efficient, long-term transgene expression by persisting episomally in the nucleus. These properties make AAV vectors promising not only for the treatment of monogenic diseases but also for tissue regenerative applications. In the context of critical-sized bone defects, current gold-standard treatments are often associated with severe side effects, highlighting the need for alternative therapy strategies. In this study, we therefore developed a gene-activated matrix (GAM) for localized AAV-mediated gene delivery for potential applications in bone regeneration, establishing a workflow that is straightforward and transferable to other therapeutic settings. Following an initial screening of AAV serotypes and transgene DNA formats, reporter gene-expressing AAV2 vectors were associated with chitosan-based scaffolds containing varying amounts of β-tricalcium phosphate (β-TCP). Analysis of AAV release revealed that incorporation of β-TCP significantly reduced AAV release from 15.7% to approximately 6.6%. Furthermore, seeding of primary ovine mesenchymal stromal cells (oMSC) onto AAV-loaded scaffolds demonstrated efficient
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.